Want to join the conversation?
$BIIB said aducanumab, its investigational treatment for early Alzheimer's disease, was granted Fast Track designation by the U.S. FDA. Aducanumab is being evaluated in 2 Phase 3 studies, ENGAGE and EMERGE, to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in people with early Alzheimer's disease.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!